Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Old API Wind-down Ltd - Ordinary Shares ARLZQ

"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently operates in two geographical markets, the United States and Canada. The firm generates most of its reven


OTCPK:ARLZQ - Post by User

Comment by Floridas2000on Aug 02, 2016 2:02pm
58 Views
Post# 25103205

RE:RE:RE:History will tell you, this is the time to.....

RE:RE:RE:History will tell you, this is the time to.....
select1011 wrote: Yosprala is not the only game in town. And what Tribute brought to this company, is falling apart.
kuatolives wrote: Horizon royalties to ARLZ have loor values; but everyone knows Yosprala is the horse pulling this cart now. You'd have to reconcile your statement against the impact this will have on sales vs floor Vimovo royalties vs peak Yosprala sales vs a % of overall revenue for the company.

 





That's incredibly false.  What tribute brought was the following:

1 - ability to go domicile outside of US
2 - further versatility of products
3 - they actually were making more money than Pozen

One provider put Vimovo on their list when it was previously off their list.  With a few concessions it can easily go off their list like it was before.  I'm not sure what you're getting at and why you're freaking out?
<< Previous
Bullboard Posts
Next >>